For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of lamivudine treatment.
Patsientide kohta, kellel tekib ravi järgselt hepatiidi retsidiveerumine, on andmed lamivudiinravi taasalustamise kasulikkuse kohta ebapiisavad.